AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00932035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosulfan blue based lymphatic mapping
Study NCT00932035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isosulfan blue based lymphatic mapping
Study NCT00932035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node dissection
Description: Undergo standard axillary lymph node dissection
Study NCT00932035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00932035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00932035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT00932035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT02662426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lingdancao granules
Description: 4 packs per time (3g/pack), three times per day
Study NCT02662426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: analogous oseltamivir phosphate capsule
Description: 1 capsule per time, twice per day
Study NCT02662426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: analogous oseltamivir phosphate capsule
Description: 1 capsule per time, twice per day
Study NCT02662426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir phosphate capsule
Description: 1 capsule per time (75mg), twice per day
Study NCT02662426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: analogous Lingdancao granules
Description: 4 packs per time, three times per day
Study NCT02662426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: analogous Lingdancao granules
Description: 4 packs per time, three times per day
Study NCT01575808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP1101
Description: Endovascular stent graft implantation
Study NCT05174338 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: Observational, data collection
Study NCT01527045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: Given PO
Study NCT01527045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT01527045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01527045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01527045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV
Study NCT01527045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplant
Study NCT01527045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplant
Study NCT01527045 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT01235663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advisory support
Description: regular advisory support to the prolong breast-feeding period
Study NCT03569358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality
Description: The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
Study NCT03569358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
Study NCT03569358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG headband
Description: The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
Study NCT03569358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG headband
Description: The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
Study NCT00418730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
Study NCT00418730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
Study NCT00418730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Description: Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
Study NCT04738994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein-enriched nutritional supplement
Description: Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
Study NCT04738994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard hospital diet
Study NCT01621984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Riding/ Hippotherapy Intervention
Description: The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
Study NCT00816010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone contact
Description: for lifestyle and compliance counseling
Study NCT04587206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348
Description: QD, PO
Study NCT04587206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study NCT02944838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Senior Change Makers Advocacy Program
Description: see description
Study NCT02944838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Senior Change Makers Physical Activity Program
Description: see description
Study NCT03696550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline (TP-434)
Description: Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)
Study NCT00200707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous bone marrow mononuclear cells
Study NCT02866162 — intervention group
Intervention type: GENETIC
Intervention: High-throughput exome sequencing
Study NCT03474263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biologic: IC14 (monoclonal antibody against human CD14)
Description: IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
Study NCT00023712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00023712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00023712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01985971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging
Study NCT00587444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: 300u/kg of heparin for CPB ACT performed. If ACT is \< 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is>480 seconds
Study NCT00587444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HH or high heparin
Description: initial dose of 450u/kg for CPB ACT performed additional bolus given if result is \<600 seconds anytime during CPB
Study NCT00587444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin concentration HC
Description: will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%
Study NCT00582699 — intervention group
Intervention type: BEHAVIORAL
Intervention: assessment interview and blood draw
Description: All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
Study NCT01047007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib 20 mg
Description: Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
Study NCT01047007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU 1000 mg/m^2/day
Description: 5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
Study NCT01047007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDDP
Description: CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.
Study NCT01047007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib 65 mg
Description: Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
Study NCT04833868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy and schroth exercise
Description: pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week hippotherapy intervention combined with Schroth exercise
Study NCT04833868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: schroth exercise
Description: pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week of Schroth exercise
Study NCT02155101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
Study NCT02155101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART with 2 NRTIs plus LPV/r (or ATV/r)
Description: Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
Study NCT02060929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
Study NCT04649216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCO371
Description: PCO371 Capsule
Study NCT00958516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102 cream
Description: LEO 29102 cream in different doses and the cream vehicle
Study NCT00742846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine + Kenalog
Description: 5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid
Study NCT04649216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PCO371
Description: \[14C\]PCO371 Oral solution
Study NCT04649216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PCO371
Description: \[14C\]PCO371 Solution for infusion
Study NCT01424358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Educational Intervention
Description: The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
Study NCT03610854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness Tracker
Description: Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
Study NCT02185261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
Study NCT04470882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with faded safety behaviors
Description: Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
Study NCT04470882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure without safety behaviors
Description: Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
Study NCT04470882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with unfaded safety behaviors
Description: Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
Study NCT02433496 — intervention group
Intervention type: OTHER
Intervention: Physician coaching
Description: The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice.
Study NCT00742846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine + Kenalog
Description: 5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space
Study NCT03819387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBF-006
Description: Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
Study NCT01597648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300 mg
Study NCT01597648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivir
Description: 1 tablet: lamivudine 150mg, zidovudine 300mg
Study NCT01597648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838510
Description: Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
Study NCT02955888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI4050
Description: Investigational Medicinal Product
Study NCT02955888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study NCT03886948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered subcutaneously (SC)
Study NCT03886948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe (PFS)
Description: PFS used to administer LY3074828
Study NCT03886948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Description: AI used to administer LY3074828
Study NCT01732705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
Study NCT00291031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Description: Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments.
Study NCT01456793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Options to Prevent Pregnancy (T.O.P.P.)
Description: Telephone-based care coordination and mobile contraceptive services
Study NCT02377843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory
Description: The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice
Study NCT02377843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Efficient
Description: The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice
Study NCT01986894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of Placebo
Study NCT01986894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Single oral dose of 4 mg pomalidomide
Study NCT01986894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Single oral dose of 20 mg pomalidomide
Study NCT01986894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose of 400 mg moxifloxacin tablet
Study NCT02895178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength exercise training
Description: Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.